CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies
Status:
Recruiting
Trial end date:
2035-09-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T
cells when given together with chemotherapy, and to see how well they work in treating
patients with CD19 positive diffuse large B-cell lymphoma or B acute lymphoblastic leukemia
that has come back or does not respond to treatment. A CAR is a genetically-engineered
receptor made so that immune cells (T cells) can attack cancer cells by recognizing and
responding to the CD19/CD22 proteins. These proteins are commonly found on diffuse large
B-cell lymphoma and B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as
cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of
cancer cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Giving CD19/CD22-CAR T cells and chemotherapy may work better in
treating patients with diffuse large B-cell lymphoma or B acute lymphoblastic leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Crystal Mackall, MD David Miklos
Collaborator:
California Institute for Regenerative Medicine (CIRM)